This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baron, A. T. Articles by Maihle, N. J. Search for Related Content PubMed PubMed Citation Articles by Baron, A. T. Articles by Maihle, N. J.

Serum sErbB1 and Epidermal Growth Factor Levels As Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer¹

Tumor Biology Program [A. T. B., J. M. L., N. J. M.], Cancer Center Statistics Unit, Department of Health Sciences Research [V. J. S.], Gynecologic Surgery, Department of Obstetrics and Gynecology [C. H. B., K. C. P.], and Division of General Surgery, Department of Surgery [S. B.], Mayo Clinic, Rochester, Minnesota 55905

Epithelial ovarian cancer (EOC) has a high mortality rate, which is due primarily to the fact that early clinical symptoms are vague and nonspecific; hence, this disease often goes undetected and untreated until in its advanced stages. Sensitive and reliable methods for detecting earlier stages of EOC are, therefore, urgently needed. Epidermal growth factor (EGF) is a ligand for EGF receptor (ErbB1); this receptor is the product of the c-erbB1 proto-oncogene. ErbB1 overexpression is common in human ovarian carcinoma-derived cell lines and tumors, in which overexpression is thought to play a critical role in tumor etiology and progression. Furthermore, ErbB1 overexpression is associated with disease recurrence and decreased patient survival. Recently, we have developed an acridinium-linked immunosorbent assay that detects a 110-kDa soluble analogue of ErbB1, i.e., sErbB1, in serum samples from healthy men and women (A. T. Baron, et al., J. Immunol. Methods, 219: 23–43, 1998). Here, we demonstrate that serum p110 sErbB1 levels are significantly lower in EOC patients with stage III or IV disease prior to (P < 0.0001) and shortly after (P < 0.0001) cytoreductive staging laparotomy than in healthy women of similar ages, whereas EGF levels are significantly higher than those of age-matched healthy women only in serum samples collected shortly after tumor debulking surgery (P < 0.0001). We observe that the preoperative serum sErbB1 concentration range of advanced stage EOC patients barely overlaps with the serum sErbB1 concentration range of healthy women. In addition, we show that serum sErbB1 and EGF levels changed temporally for some EOC patients who were surgically debulked of tumor and who provided a second serum sample during the course of combination chemotherapy. Finally, we observe a significant positive association between sErbB1 and EGF levels only in serum samples of EOC patients collected prior to cytoreductive surgery (correlation coefficient = 0.61968; P = 0.0027). These data suggest that epithelial ovarian tumors concomitantly affect serum sErbB1 and EGF levels. In conclusion, these data indicate that serum sErbB1 and EGF (postoperative only) levels are significantly different between EOC patients and healthy women and that altered and/or changing serum sErbB1 and EGF levels may provide important diagnostic and/or prognostic information useful for the management of patients with EOC.

This article has been cited by other articles:

				S. Crawford, D. Belajic, J. Wei, J. P. Riley, P. J. Dunford, S. Bembenek, A. Fourie, J. P. Edwards, L. Karlsson, A. Brunmark, et al. A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker Mol. Cancer Ther., March 1, 2008; 7(3): 492 - 499. [Abstract] [Full Text] [PDF]

				S. E. D. Webb, S. K. Roberts, S. R. Needham, C. J. Tynan, D. J. Rolfe, M. D. Winn, D. T. Clarke, R. Barraclough, and M. L. Martin-Fernandez Single-Molecule Imaging and Fluorescence Lifetime Imaging Microscopy Show Different Structures for High- and Low-Affinity Epidermal Growth Factor Receptors in A431 Cells Biophys. J., February 1, 2008; 94(3): 803 - 819. [Abstract] [Full Text] [PDF]

				H. Y. Zhou, Y. L. Pon, and A. S. T. Wong Synergistic Effects of Epidermal Growth Factor and Hepatocyte Growth Factor on Human Ovarian Cancer Cell Invasion and Migration: Role of Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase Endocrinology, November 1, 2007; 148(11): 5195 - 5208. [Abstract] [Full Text] [PDF]

				S. F. Shariat, K. Bensalah, J. A. Karam, C. G. Roehrborn, A. Gallina, Y. Lotan, K. M. Slawin, and P. I. Karakiewicz Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer Clin. Cancer Res., September 15, 2007; 13(18): 5377 - 5384. [Abstract] [Full Text] [PDF]

				J. M. Lafky, A. T. Baron, E. M. Cora, D. W. Hillman, V. J. Suman, E. A. Perez, J. N. Ingle, and N. J. Maihle Serum Soluble Epidermal Growth Factor Receptor Concentrations Decrease in Postmenopausal Metastatic Breast Cancer Patients Treated with Letrozole Cancer Res., April 15, 2005; 65(8): 3059 - 3062. [Abstract] [Full Text] [PDF]

				E. Gorelik, D. P. Landsittel, A. M. Marrangoni, F. Modugno, L. Velikokhatnaya, M. T. Winans, W. L. Bigbee, R. B. Herberman, and A. E. Lokshin Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 981 - 987. [Abstract] [Full Text] [PDF]

				A. T. Baron, C. H. Boardman, J. M. Lafky, A. Rademaker, D. Liu, D. A. Fishman, K. C. Podratz, and N. J. Maihle Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 306 - 318. [Abstract] [Full Text] [PDF]

				L. G. Sheffield and J. J. Gavinski Proteomics Methods for Probing Molecular Mechanisms in Signal Transduction J Dairy Sci, July 1, 2003; 86(13_suppl): E115 - 124. [Abstract] [Full Text] [PDF]

				R. C. Bast Jr Status of Tumor Markers in Ovarian Cancer Screening J. Clin. Oncol., May 15, 2003; 21(90100): 200s - 205. [Abstract] [Full Text] [PDF]

				J. L. REITER and N. J. MAIHLE Characterization and Expression of Novel 60-kDa and 110-kDa EGFR Isoforms in Human Placenta Ann. N.Y. Acad. Sci., May 1, 2003; 995(1): 39 - 47. [Abstract] [Full Text] [PDF]

				L. G. Sheffield and J. J. Gavinski Proteomics methods for probing molecular mechanisms in signal transduction J Anim Sci, March 1, 2003; 81(suppl_3): 48 - 57. [Abstract] [Full Text] [PDF]

				A. T. Baron, E. M. Cora, J. M. Lafky, C. H. Boardman, M. C. Buenafe, A. Rademaker, D. Liu, D. A. Fishman, K. C. Podratz, and N. J. Maihle Soluble Epidermal Growth Factor Receptor (sEGFR/sErbB1) as a Potential Risk, Screening, and Diagnostic Serum Biomarker of Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 103 - 113. [Abstract] [Full Text] [PDF]

				E. A. Perez, L. Geeraerts, V. J. Suman, A. A. Adjei, A. T. Baron, A. K. Hatfield, N. Maihle, J. C. Michalak, S. A. Kuross, J. W. Kugler, et al. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer Ann. Onc., August 1, 2002; 13(8): 1225 - 1235. [Abstract] [Full Text] [PDF]

				L. D. Dunfield, E. J. C. Dwyer, and M. W. Nachtigal TGF{beta}-Induced Smad Signaling Remains Intact in Primary Human Ovarian Cancer Cells Endocrinology, April 1, 2002; 143(4): 1174 - 1181. [Abstract] [Full Text] [PDF]

				A. T. Baron, J. M. Lafky, V. J. Suman, D. W. Hillman, M. C. Buenafe, C. H. Boardman, K. C. Podratz, E. A. Perez, and N. J. Maihle A Preliminary Study of Serum Concentrations of Soluble Epidermal Growth Factor Receptor (sErbB1), Gonadotropins, and Steroid Hormones in Healthy Men and Women Cancer Epidemiol. Biomarkers Prev., November 1, 2001; 10(11): 1175 - 1185. [Abstract] [Full Text] [PDF]

				S. M. Ellerbroek, J. M. Halbleib, M. Benavidez, J. K. Warmka, E. V. Wattenberg, M. S. Stack, and L. G. Hudson Phosphatidylinositol 3-Kinase Activity in Epidermal Growth Factor-stimulated Matrix Metalloproteinase-9 Production and Cell Surface Association Cancer Res., March 1, 2001; 61(5): 1855 - 1861. [Abstract] [Full Text]